SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Feb 21, 2022–
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before the market opens on Thursday, February 24, 2022.
United Therapeutics will host a public webcast Thursday, February 24, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one week and can be accessed at the same location.
United Therapeutics: Enabling Inspiration
We build on the strength of our research and development expertise and a distinctive, entrepreneurial culture that encourages diversity, innovation, creativity, sustainability, and, simply, fun. Since inception, our mission has been to find a cure for pulmonary arterial hypertension and other life-threatening diseases. Toward this goal we have successfully gained FDA approval for five medicines, we are always conducting new clinical trials, and we are working to create an unlimited supply of manufactured organs for transplantation.
We are the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. At the same time, we seek to provide our shareholders with superior financial performance and our communities with earth-sensitive energy utilization.
You can learn more about what it means to be a PBC here: unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our mission to find a cure for pulmonary hypertension and other life-threatening diseases, our ongoing and future clinical trials and other research and development efforts, and our goals of furthering our public benefit purpose, providing superior financial performance for shareholders, and providing our communities with earth-sensitive energy utilization. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 21, 2022 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View source version on businesswire.com:https://www.businesswire.com/news/home/20220221005093/en/
CONTACT: Dewey Steadman at (202) 919-4097
Email:[email protected]
KEYWORD: NORTH CAROLINA MARYLAND UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY
SOURCE: United Therapeutics Corporation
Copyright Business Wire 2022.
PUB: 02/21/2022 06:00 AM/DISC: 02/21/2022 06:02 AM
Copyright Business Wire 2022.
